Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £2.44m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

26 Sep 2006 16:46

Azure Holdings PLC26 September 2006 Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2006 Chairman's statement I am pleased to present the interim accounts for the six months ended 30 June2006. In the six months to 30 June 2006 the Company announced a loss after taxation of£138,000 (2005: £74,000). The figures should not reflect the future of the Company, which hopefully willmove forward successfully as ValiRx plc from early next month, because, asannounced on 11 September 2006, the reverse acquisition of ValiRx Limited hasbeen agreed and is subject to shareholders approval at the EGM scheduled for 2October 2006. If all the resolutions at that meeting are approved, the Company will retain itsAIM quotation and I will resign as Chairman leaving the new board and GerryDesler, Finance Director from the old board, to run the Company. Barry GoldChairman 26 September 2006 Azure Holdings plc Profit and Loss Account for the six months ended 30 June 2006 6 months ended 6 months ended Year ended 31 30 June 2006 30 June 2005 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000 Turnover - - - Administrative expenses (138) (74) (134) Operating loss (138) (74) (134) Loss on ordinary activities before taxation (138) (74) (134) Tax on loss on ordinary activities - - - Loss on ordinary activities after taxation (138) (74) (134) Retained loss for the period (138) (74) (134) Loss per ordinary share (0.12p) (0.15p) (0.28p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains and losses. Azure Holdings plc Balance Sheet as at 30 June 2006 30 June 2006 30 June 2005 31 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000Current assetsDebtors 9 3 1Cash at bank and in hand 127 1 1 136 4 2 Creditors: amounts falling due within one year (103) (147) (205) Net current assets/(liabilities) 33 (143) (203) Total assets less current liabilities 33 (143) (203) Net (liabilities)/assets 33 (143) (203) Capital and reservesCalled up Share Capital 6,271 5,475 5,475Share Premium 9,858 10,279 10,279Profit and loss account (16,096) (15,897) (15,957) Equity shareholders funds 33 (143) (203) Azure Holdings plc Cash Flow Statement for the six months ended 30 June 2006 6 months ended 6 months ended 30 June 2006 30 June 2005 (unaudited) (unaudited) £'000 £'000Net cash inflow (outflow) from operating activities (249) (13) FinancingIssue of ordinary shares 796 - Share premium reduction arising onconversion of loan stock (421) - Increase/(Decrease) in cash 126 (13) Azure Holdings plc Notes to the Interim Results 1. The interim results are unaudited and do not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. Thefigures for the year ended 31 December 2005 have been extracted from thestatutory accounts filed with the registrar of companies on which the auditorsgave an unqualified report. 2. The interim results have been prepared using the accountingpolicies set out in the statutory accounts for the year ended 31 December 2005. 3. The comparative figures for the unaudited interim results for theperiod ended 30 June 2005 are stated as announced on 27 September 2005. 4. Loss per share The loss per share for the six months ended 30 June 2006 has been calculated onthe basis of the loss after taxation for the period of £138,000 (2005: £74,000) and the weighted average number of shares in issue during the period of118,717,810 (2005: 48,317,569). . 5. The directors do not propose to pay a dividend for the period. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant
24th Feb 20157:00 amRNSSuccessful 1st Results from VAL201 Clinical Trial
11th Feb 20157:00 amRNSNew European Patent Grant
5th Feb 20157:00 amRNSAcquisition
15th Jan 20157:00 amRNSClinical Trial and Development Update
18th Dec 20147:00 amRNSIssue of Equity
4th Dec 20147:00 amRNSValiSeek Scientific Update
26th Nov 20147:00 amRNSRe: Progress with Trial Recruitment and Testing
13th Nov 20147:00 amRNSCollaboration Agreement
7th Nov 201410:23 amRNSHolding(s) in Company
3rd Nov 201411:00 amRNSApproved Clinical Trial Update
31st Oct 20147:00 amRNSTotal Voting Rights
23rd Oct 201410:45 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.